FOLFOXIRI FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.
Fiche publication
Date publication
mars 2020
Journal
World journal of gastrointestinal oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr FEIN Francine, Dr VERNEREY Dewi, Dr VIENOT Angélique, Dr KIM Stephano, Mme MEURISSE Aurélia
Tous les auteurs :
Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d'Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D
Lien Pubmed
Résumé
FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibility in colorectal cancer.
Mots clés
Advanced pancreatic cancer, Cohort study, FOLFIRINOX, FOLFOXIRI, First-line chemotherapy, Propensity score
Référence
World J Gastrointest Oncol. 2020 Mar 15;12(3):332-346